The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab
Başlık:
The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab;
in women with locally advanced, inflammatory, or early-stage human;
epidermal growth factor receptor 2-positive breast cancer: Turkish;
Oncology Group study
Ozdemir, O; Zengel, B; Yildiz, Y; Uluc, BO; Cabuk, D; Ozden, E; Salim, DK; Paydas, S; Demir, A; Diker, O; Pilanci, KN; Sonmez, OU; Vatansever, S; Dogan, I; Gulmez, A; Cakar, B; Gursoy, P; Yildirim, ME; Ayhan, M; Karadurmus, N; Aykan, MB; Cevik, GT; Sakalar, T; Hacibekiroglu, I; Gulbagci, BB; Dincer, M; Garbioglu, DB; Kemal, Y; Nayir, E; Taskaynatan, H; Yilmaz, M; Avci, O; Sari, M; Coban, E; Atci, MM; Esen, SA; Telli, TA; Karatas, F; Inal, A; Demir, H; Kalkan, NO; Yilmaz, C; Tasli, F; Alacacioglu, A
Tarih:
2022
Özet:
In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted by the Turkish Oncology Group (TOG) with data collected from 32 centers. Our study was multicentric, and a total of 364 patients were included. The median age of the patients was 49 years (18-85 years). Two hundred fifteen (60%) of the cases were hormone receptor/HER2+ positive(ER+ or PR+, or both), and 149 (40%) of them were HER2-rich (ER and PR negative). The number of complete responses was 124 (54%) in the docetaxel+trastuzumab+pertuzumab arm and 102 (45%) in the paclitaxel+trastuzumab+pertuzumab arm, and there was no difference between the groups in terms of complete response. In 226 (62%) patients with complete response, a significant correlation was found with DCIS, tumor focality, removed lymph node, and ER status P < 0.05. Anemia, nausea, vomiting, myalgia, alopecia, and mucosal inflammation were significantly higher in the docetaxel arm, P < 0.05. In our study, no statistical difference was found between the before-after echocardiography values. DCIS positivity in biopsy before neoadjuvant chemotherapy, tumor focality; the number of lymph nodes removed and ER status were found to be associated with pCR. In conclusion, we think that studies evaluating pCR-related clinicopathological variables and radiological imaging features will play a critical role in the development of nonsurgical treatment approaches.
Tüm öğe kaydını göster